Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex™ and tamoxifen alone or in combination' (ATAC) trial

British Journal of Cancer

Volumn 85, Issue 3, 2001, Pages 317-324

  Arcasoy, Murat O ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Arimidex; Aromatase inhibitor; Breast cancer; Oestradiol; Oestrogen; Tamoxifen

Indexed keywords

ANASTROZOLE; NORTAMOXIFEN; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; SAFETY; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 0035800525     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1925     Document Type: Article

References (33)

1. Pharmacokinetic studies with Nolvadex
2. What we know and don't know about the pharmacokinetics of tamoxifen
3. On the treatment of inoperable cases of carcinoma in mamma; suggestion for new method of treatment with illustrative cases
4. Validated assay for the quantification of anastrozole in human plasma by capillary gas chromatography/63Ni electron capture detection
5. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the TARGET (Tamoxifen or Arimidex™ Randomized Group Efficacy and Tolerability) study
6. On oophorectomy in cancer of the breast
7. Aromatase inhibitors and their antitumor effects in model systems
8. Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications
9. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Result of overview analysis of two phase III trials
10. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
11. The bioavailability of tamoxifen: New findings and their clinical implications
12. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route
13. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer
14. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
15. The relevance of preclinical models to the treatment of postmenopausal breast cancer
16. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31, 000 recurrences and 24.000 deaths among 75, 000 women
17. Tamoxifen for early breast cancer: An overview of the randomised trials
18. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
19. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intra-tumor estrogen levels
20. Source of estrogen production in postmenopausal women
21. Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
22. Recent advances in endocrine therapy of breast cancer
23. Use of tamoxifen for breast cancer: Twenty-eight years later
24. Effect of oestrogen receptor status and time on the intratumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human breast cancer
25. Effect of tamoxifen (ICI 46474) on initiation and growth of DMBA-induced rat mammary carcinoma
26. Formation of solid human mammary carcinoma in vitro
27. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
28. Effect of obesity on conversion of plasma androstenedione to oestrone in postmenopausal women with and without endometrial cancer
29. The importance of local synthesis of estrogen within the breast
30. A re-evaluation of the pharmacokinetics of tamoxifen
31. New insights into the tamoxifen pharmacokinetics constitute a basis for a loading dose scheme
32. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
33. Arimidex (ZD1033): G selective, potent inhibitor of aromatase in postmenopausal female volunteers